1. Of the judgment of the court of first instance, the part against Defendant A Co., Ltd. or D which exceeds the amount ordered to be paid below.

1. The reasons why the court should explain this part of the basic facts are stated in the part of the judgment of the court of first instance, i.e., Chapters 5, 12, and 15 of the judgment of the court of first instance, with the exception that the part stated in the 5th through 15 of the judgment of the court of first instance is as follows.

Since it is the same, it is accepted by the main sentence of Article 420 of the Civil Procedure Act.

2) Defendant East Drug Co., Ltd. (hereinafter referred to as “Dong East Drug”), Il East Drug Co., Ltd. (hereinafter referred to as “Seoul East Drug”), Taebol Co., Ltd. (hereinafter referred to as “T Taebol Medicine”), Taebol Co., Ltd. (hereinafter referred to as “Cina”), Cina Co., Ltd. (hereinafter referred to as “Cina”), and Jongbol Holdings Co., Ltd. (hereinafter referred to as “Cina”), are companies engaged in the manufacture, sale, etc. of drugs.

On November 2, 2013, Defendant branch trading company divided the company into a personal division method as of November 2, 2013. Accordingly, the establishment of the closing party corporation, which is the above defendant's lawsuit taking over (hereinafter "the closing party"), thereby comprehensively taking over the pharmaceutical business sector among the above defendant's business sector, including all rights and obligations related to the lawsuit in this case.

A person shall be appointed.

2. Determination as to claims against Defendant A, B, C, and D

A. According to the facts of recognition of the above illegal act committed by Defendant D, as an employee of Defendant A, a same-sex testing institution, prepared a false report on the results of the same-sex testing by manipulating test data about E, thereby allowing the head of the Food and Drug Administration to engage in an illegal act of allowing the head of the Food and Drug Administration to modify items manufactured or manufactured medicines for E and each of the above entrusted production drugs.

Defendant A and D did not manipulate test data regarding Defendant D, but did not accurately state the test process.